In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...

The Department of Health and Human Services, headed by RFK Jr., is responding to reports that the CDC will begin researching ...

Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ...

Martin Makary, President Donald Trump's nominee to run the U.S. FDA, will be tasked with maintaining the agency's gold ...

The National Childhood Vaccine Injury Act of 1986 removed the economic incentive that held vaccine developers accountable for vaccine safety. Reforms, including properly designed trials, are needed to ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus ... and a decision on the label extension application of IXCHIQ ® in the European Union (EU), Norway ...

Vaxart (VXRT) announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus ...

Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI12, with support from the EU Horizon Europe program ...

Valneva is focused on expanding the vaccine's label and access. In the third quarter of 2024, the Company expanded its partnership with CEPI 12, with support from the EU Horizon Europe program, ...